Clinical trials: Stage IV Melanoma
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Melanoma
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
The purpose of this study is to determine whether a vaccine composed of patients' own melanoma cells treated with the chemical, dinitrophenyl (DNP)(called a hapten), is safe and stimulates an immune response to patients' own…
- Trial name
- NCT00257465
- Testing
- Autologous, DNP-modified vaccine (M-Vax), Autologous, DNP-Modified Melanoma Vaccine, Autologous, DNP-Modified Vaccine
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- AVAX Technologies
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Recurrent Melanoma, Stage IIIA Melanoma
FDG-PET in Advanced Melanoma
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02236546
- Testing
- [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
IFx-Hu2.0 Expanded Access Program
Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or…
- Conditions
- Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT04853602
- Testing
- IFx-Hu2.0
- Sponsor
- TuHURA Biosciences, Inc.
Melanoma (Skin), Metastatic Cancer
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00039234
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 19 sites in United States, Canada and 2 more
- Sponsor
- Maxim Pharmaceuticals
Unresectable Melanoma, Metastatic Cutaneous Melanoma
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells…
- Conditions
- Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
- Trial name
- DUET-MEL (NCT07627698)
- Testing
- EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Malignant Melanoma
Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma
RATIONALE:Anti-melanoma activity of Ipilimumab both as a single therapy and in association with melanoma peptides has been shown as well as synergy between radiation therapy and anti-CTLA-A mAb in several tumor animal models for…
- Trial name
- Mel-Ipi-Rx (NCT01557114)
- Testing
- Ipilimumab, Radiotherapy
- Where
- 2 sites in France
- Volunteers
- 19 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Melanoma (Skin)
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00081042
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Melanoma
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
This open-label, dose-escalation study of vemurafenib in combination with cobimetinib will evaluate the safety, tolerability and pharmacokinetics in participants with BRAFV600 mutation-positive metastatic melanoma.
- Trial name
- NCT01271803
- Testing
- Cobimetinib, vemurafenib
- Where
- 10 sites in United States, Australia
- Volunteers
- 131 people
- Sponsor
- Hoffmann-La Roche
Melanoma
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in neoadjuvant treatment of patients with Stage III-IV…
- Trial name
- NCT06212388
- Testing
- Ex-vivo expanded allogeneic γδ T cells, Recombinant human interferon α1b, Pembrolizumab
- Volunteers
- 10 people
- Sponsor
- Xijing Hospital
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 10 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma
Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders
This is a single-arm, single-center, open-label, phase IIa study evaluating the safety, feasibility and efficacy of Faecal Microbiota Transplant (FMT) to cancer patients not responding to ICI therapy, using ICI-responders as…
- Conditions
- Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, MSI-High
- Trial name
- MITRIC (NCT05286294)
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
BRAF V600 Mutated-Stage III/IV Melanoma
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
This was a retrospective chart review study of all proto-oncogene B-Raf (BRAF) V600-mutated patients who received adjuvant checkpoint inhibitor (CPI) therapy, relapsed locoregionally or distantly, and were again resected to no…
- Trial name
- NCT06557291
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Novartis
Melanoma Metastatic
Interleukin-2 in Metastatic Melanoma
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
- Trial name
- NCT01702896
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Western Regional Medical Center
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
- Trial name
- NCT04987996
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Sponsor
- Providence Health & Services